By Nancy Parrish, Staff Writer
The Frederick National Laboratory for Cancer Research (FNLCR) recently formed a partnership with the Pancreatic Cancer Action Network (PanCAN) to award a one-year fellowship to two scientists whose research will help lead to new therapies for pancreatic cancer. The scientists will focus on KRAS, a gene in the RAS family that is mutated in 95 percent of pancreatic cancers, according to the National Cancer Institute (NCI).
“We are delighted to be partnering with the Pancreatic Cancer Action Network to support research aligned with the RAS Initiative and will be working closely with the two fellows, Drs. Hunter and McGregor, to optimize research outcomes for clinical benefit,” said Frank McCormick, Ph.D., in an article on the PanCAN website. McCormick is the director of the RAS Initiative at FNLCR, which is operated by Leidos Biomedical Research for NCI.
For more details about the partnership, see the Pancreatic Cancer Action Network website.